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1. Introduction
Influenza virus is a perpetual economic burden that causes a significant morbidity and mor-
tality rate in humans. Globally, the reported cases of seasonal influenza viruses (SIVs) rise up 
to 3–5 million during epidemics with an estimated death toll of 290,000–650,000 per year [1]. 
The Global Influenza Surveillance and Response System (GISRS), a surveillance system of the 
World Health Organization (WHO), analyses the incidences of avian and zoonotic influenza 
virus to accurately estimate the severity of the disease. As of March 5–18, 2018, GISRS-WHO 
has reported 46.8% cases of influenza A virus (where 64% were influenza A(H1N1)pdm09 
cases and 36% were infected with H3N2) and 53.2% of influenza B virus (where 91% were 
B-Yamagata strain and 9% were B-Victoria) [2]. The co-morbidity condition (such as diabetes, 
heart or liver disease) or the immuno-compromised condition of patients is the predominant 
cause of mortality associated with influenza virus.
Influenza virus belongs to the Orthomyxoviridae family and is categorized as influenza A virus 
(IAV), influenza B virus (IBV), and influenza C virus (ICV). The genome of influenza virus is 
segmented with 8 negative-sense single-stranded viral RNA (vRNA) strands which code for 
11 proteins in cases of IAV and IAB, whereas IAC has seven vRNA segments that code for 
nine proteins. These segments are named after their main proteins such as segment 1-PB2 
(polymerase basic 2), segment 2-PB1 (polymerase basic 1), segment 3-PA (polymerase acid), 
segment 4-HA (hemagglutinin), segment 5-NP (nucleoprotein), segment 6-NA (neuramini-
dase), segment 7-M (matrix), and segment 8-NS (non-structural) [3]. Influenza vRNA has 
heterotrimeric RNA-dependent RNA polymerase (RdRp) at the 5′ and 3′ end of the segment 
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and the internal part of vRNA is bound with several nucleoproteins (NP) forming viral 
ribonucleoprotein complexes (vRNP) [4]. Hemagglutinin (HA) and neuraminidase (NA) are 
envelope glycoproteins responsible for the antigenic variation and the generation of different 
strains of influenza virus. HAs are of 16 subtypes (H1–H16) and NA has nine subtypes (N1-
N9) [5]. As a result of the antigenic drift, SIVs are generated due to several point mutations 
in the HA and NA genes caused by RdRp [6]. Thus, the antibodies generated during primary 
infection with the influenza virus are unable to neutralize the drifted strains of SIVs, leading 
to epidemics or pandemics. Considerable numbers of individuals are always at risk of getting 
infected with influenza viruses, thus creating a state of alertness. In addition to SIVs, there are 
several pandemic viruses generated due to the antigenic shift, where the newly drifted strains 
of viruses have the ability to cross species barriers, as a result of the re-assortment of a viral 
genome with other influenza viruses (human or non-human).
2. Transmission
The natural reservoirs of IAV are duck and waterfowl allowing direct virus transmission 
to other avian hosts as well as in others via crossing species barrier such as in humans, 
Figure 1. Transmission cycle of IAV: The triangle in the figure describes the most important transmission cycle of IAV, 
where the virus is directly transmitted from the natural host, duck to avian, and further transmitted to the human, or the 
virus is transmitted from duck to human by inter-species transmission or via pig where pig acts as an intermediate host 
between the duck and the human. The other low pathogenic hosts of IAV are cat, horse, dog, ferret, seal, and whale. The 
subtypes of IAVs responsible for causing influenza in their host are also mentioned.
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cats, pigs, horses, ferrets, seals, and whales (Figure 1). Avian IAV such as H5N1 and 
H9N2 are known to cause bird flu, whereas H1N1 and H3N2 are responsible for swine 
flu. IAVs are also categorized as seasonal and pandemic based on genetic variation and 
the severity of influenza disease; IAV transmission occurs by direct or indirect contact, 
inhaling virus-infected droplets or small droplet nuclei, being exposed to diseased poul-
try, feeding raw or undercooked poultry, transplacental transmission, or drinking water 
contaminated by viruses [7]. The serological evidence validated that human-to-human 
transmission of influenza viruses is inefficient; however, in some rare cases human-to-
human transmission was observed during an outbreak of the highly pathogenic avian 
influenza viruses (HPAI) of H5N1 [8]. Influenza virus enters the human body through 
the respiratory tract and its incubation period is 1–7 days. The common symptoms associ-
ated with influenza are respiratory distress, fever, headache, cold, abdominal pain and 
joint pain [9]. With the progression of the disease, other symptoms observed are bloody 
sputum and pneumonia that further cause respiratory failure leading to acute respira-
tory distress syndrome (ARDS) [10]. IAV-infected patients can be diagnosed by reverse 
transcription-polymerase chain reaction (RT-PCR), viral culture, and the high levels of 
HA antigen- specific neutralizing antibodies.
3. Life cycle of influenza A virus
The IAV enters in the host cell by binding with surface receptors possessing sialic acid 
moiety. Viruses are internalized by endocytosis and the uncoating of the virus by matrix 
protein 2, an ion channel. The vRNA is released in the cytoplasm and is imported to the 
nucleus where vRNA is transcribed and replicated by using its polymerase [11]. Thus, 
these steps lead to the synthesis of a positive sense complementary RNA (cRNA) and viral 
messenger RNA (vmRNA) with 5’cap and 3′ poly (A) tail. The influenza virus polymerase 
does not exhibit capping activity at the 5’end; hence, they have to depend on host-capped 
mRNAs where they capture its 5’cap, a process known as cap snatching [12]. The viral 
m-RNA is translated in the cytoplasm after being exported from the nucleus and viral pro-
teins, and nucleoproteins are synthesized by cellular ribosomes. Translated viral proteins 
re-enter the nucleus and bind to the vRNAs to generate viral ribonucleoproteins (vRNPs). 
Following nuclear export, progeny vRNPs and viral proteins are assembled to form virions 
which later egress from the host cell.
4. Pandemics and outbreaks of human influenza A virus
The prominent IAVs causing pandemics and outbreaks in various parts of the world are 
shown in the Figures 2 and 3, respectively. The 1918 spread of human influenza A(H1N1) 
virus has caused death of approximately 40–50 million people worldwide. This virus had 
again emerged in 2009 and caused a death toll of 4100 people. The clinical presentations were 
similar to the earlier strain that led to a less severe response. The twenty-first-century influ-
enza viruses that cause infections in humans are briefly discussed below.
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4.1. Influenza A(H5N1) virus
The first outbreak of human infection due to influenza A(H5N1) virus occurred in Hong Kong 
in 1997 with 18 cases and 6 deaths, following its re-emergence in regions of Southeast Asia 
during 2003, where 392 individuals were infected and 247 fatal outcomes were reported [13]. 
Figure 2. The pandemics of influenza A viruses. Noted influenza A virus pandemics are shown in the figure till 2018.
Figure 3. Recent outbreaks of influenza A virus in humans. The prominent influenza A viruses of twenty-first century 
causing most number of cases are shown in the picture.
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This HPAI H5N1 virus further infected humans as well as migratory birds. The reported 
mortality rate was ~60% of the infected human population [14] and ~6000 deaths of migratory 
birds have been reported in Western China [15, 16].
4.2. Influenza A(H1N1)pdm09 virus
The first human infection from pandemic influenza A(H1N1)2009 virus was reported in 
Mexico and the United States in March 2009, and later it was transmitted globally [17]. The 
number of cases reported worldwide to the WHO in the period from March to September 
2009 was 340,000 with 4100 deaths. In India, influenza A(H1N1)2009 was the pandemic, with 
10,036 laboratory-reported cases and 308 deaths. The susceptible age groups infected were 
children of age less than 5 years and adults of more than 65 years, while pregnant women 
were at high risk of infection [18].
4.3. Influenza A(H7N9) virus
A highly pathogenic novel strain of IAV is H7N9, first reported in China in 2013. The Chinese 
Center for Disease Control and Prevention (China CDC) has actively investigated the first 82 
patients infected with influenza A(H7N9) in the provinces of China [19] where the number 
of reported cases was 131 with 32 deaths. Based on the weekly report on April 20, 2017, the 
WHO has identified 1393 laboratory-observed cases of H7N9 virus with 534 deaths. Further, 
the WHO has assessed that within 2 months of the H7N9 outbreak, the number of cases were 
as many as of H5N1 in 10 years and till date cases of H7N9 are reported [20].
5. Immunobiology
Influenza viruses enter in humans through the respiratory tract by the oral or nasal route 
and the first barrier for the virus is to cross the mucous layer surrounding the respiratory 
epithelium. Then, through the mucous layer, influenza virus has to attach and internalize 
these epithelial cells to cause infection. The host defense mechanism is activated to prohibit 
the spread of the virus. Thus, the pattern recognition receptors (PRRs) detect the pathogen-
associated molecular patterns (PAMPs) of the infectious viral agents and activate the host’s 
innate immune system by the secretion of type-I interferons, pro-inflammatory cytokines 
and chemokines [21]. Respiratory tract cells such as macrophages, dendritic cells (DCs), 
pneumocytes and plasmacytoid DCs (pDCs) actively participate in production of type-I 
interferons that stimulates a pool of genes called interferon-stimulated genes (ISGs) (men-
tioned in Table 1) which enhance the antiviral activity of host defense system [22, 23]. These 
PRRs include the toll-like receptors such as TLR3 that recognizes the viral dsRNA present 
in infected cells; TLR7 and TLR8 detect viral ssRNA present in endosomes of infected cells; 
retinoic acid-inducible gene I (RIG-I) recognizes the virus present in the cytosol of infected 
cells [24]. The human respiratory epithelial cells constitutively express TLR3 that induces 
the generation of pro-inflammatory cytokines on the detection of influenza virus that stimu-
lates the infiltration of leukocytes and CD8+ T cells restricting virus replication [25]. These 
Introductory Chapter: Human Influenza A Virus Infection - Global...
http://dx.doi.org/10.5772/intechopen.77350
7
pro-inflammatory cytokines cause local inflammation and fever that activate the adaptive 
immune response against influenza virus. Chemokines instruct downstream immune cells 
by recruiting neutrophils, monocytes and natural killer (NK) cells to the respiratory tract. 
NK cells target and eliminate the virus-infected epithelial cells initiating viral clearance 
[26]. Monocytes and neutrophils participate in the removal of dead cells infected with virus. 
Alveolar macrophages cause the phagocytic clearance of infected cells, a crucial step for virus 
clearance [27]. The innate and adaptive immune system works hand in hand for the clearance 
of the influenza virus from the host system.
6. Antiviral therapeutics
Numerous antiviral drugs inhibiting influenza viruses are available. The most targeted sites 
for restricting influenza viruses are matrix protein 2 and NA, inhibited by antivirals such as 
adamantanes (amantadine and rimantadine), oseltamivir, and zanamivir [28]. The adaman-
tanes interfere with viral uncoating and had shown toxic effects that lead to the generation of 
adamantanes-resistant strains of the influenza virus. Furthermore, the budding off progeny 
virions from host cells is impeded by the neuraminidase inhibitors that caused only one round 
of replication, hence preventing the spread of infection. Influenza viruses such as influenza 
A(H3N2) and A(H1N1)pdm09 were observed to be resistant for adamantanes; therefore, for 
the clinical treatment of influenza virus A, adamantanes are not recommended. However, 
IAV and influenza B virus are susceptible to oseltamivir and zanamivir [29]. The other poten-
tial targeted sites are viral entry, HA, pH-dependent endosomal fusion, nucleoproteins and 
polymerase proteins of influenza viruses. HA1 and HA2 play key roles in the invasion of 
the influenza virus in target host cells. HA1 binds with the sialic acid receptors while HA2 
Interferon-stimulated genes (ISGs) Intracellular location Mode of action
Cholesterol 25-hydroxylase (CH25H) Cytosol Inhibits fusion of virus with host cell membrane
2ʹ-5ʹ-Oligoadenylate synthase (OAS) 
and RNase L
Cytosol Stimulates cleavage of viral RNA
Protein kinase R (PKR) Cytosol Inhibits translation and activates 
downstream NF-κB pathway
ISG15 Cytosol Ubiquitin-like protein that targets newly 
translated viral proteins for modification
Tripartite motif-containing protein 22 
(TRIM22)
Nucleus Binds with nucleocapsid for proteasomal 
degradation
MX1 Nucleus Inhibits viral transcription in nucleus
IFITM3 and other IFN-inducible 
transmembrane (IFITM) proteins
Endosomes Inhibits viral attachment, fusion and 
endocytosis
Viperin Lipid droplets and the cytosolic 
face of the endoplasmic reticulum
Inhibits egression of virus by blocking 
formation of the lipid raft
Table 1. Role of pertinent interferon-stimulated genes (ISG) in controlling influenza virus infection (adapted from Ref. [4]).
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contributes in the fusion and internalization by endocytosis. Furthermore, a novel antiviral 
N-stearoyllipopeptide of C18-ARLPR inhibits the viral replication of influenza A/Puerto 
Rico/8/34 (H1N1) and A/Aichi/2/68 (H3N2) effectively with low toxicity [30]. This peptide 
adequately binds to the sialic acid-binding site of HA1 subunit due to its structural similarity.
7. Complementary and alternative medicine (CAM)
The National Centre for Complementary and Integrative Health-National Institute of Health 
(NCCIH-NIH), the United States, describes complementary and alternative medicine (CAM) as a 
collection of varied medicinal practices, natural products, and health-care systems, different from 
conventional medicine [31]. CAMs treat the disease effectively with fewer side effects and low 
toxicity [32]. Several plant products are globally applied for the treatment of influenza, though 
the mechanism of their action is still unknown. The extracts of plants are prepared at very high 
dilution and are given in small doses. The interaction of active components of plant extracts 
and viral proteins of the influenza virus is further explored for discovering a potent organic 
antiviral against a pandemic virus such as H1N1. Some of the reported natural compounds for 
the treatment of human influenza are baicalin, tinosporon, allicin, curcumin, ursolic acid, car-
vacrol, ajoene, methanol, andrographolide, coumarin, theaflavin, and eugenol [33]. In in silico 
study, these natural compounds blocked H1N1 NA effectively with significant values of bind-
ing energies. Several traditional plants such as Trachyspermum ammi, Ocimum sanctum, Zingiber 
officinalis, Allium sativum, Curcuma longa, Tinospora cordifolia, and Mentha piperita are potential 
antiviral agents against H1N1 swine flu. Another plant-based antiviral agent, ginseng (Panax 
quinquefolium), has triterpenes and saponins that are the potent inhibitors of influenza A(H1N1)
pdm09 [34]. The CAM therapies for the treatment of influenza virus also include influenzinum 
that induces cytokine release from macrophages and furthermore activates the innate immune 
response [3]. In a study, IAV H3N2-infected MDCK cells were treated with influenzinum and it 
was observed that there was no cytotoxic effect due to influenzinum, yet the morphology of cells 
were altered [35].
8. Prevention and control
The transmission of influenza virus between humans and other hosts like avian and swine was 
reported to be possible and significantly caused pandemics in various countries [36]. The viruses 
responsible for infecting humans are HPAI or low-pathogenicity avian influenza (LPAI) viruses. 
Owing to the enormous ability of re-assortment (due to shift and drift) in influenza viruses, abso-
lute prediction of the responsible subtype(s) for the next pandemic infection is impractical. Thus, 
a vaccine which can effectively target a broad range of influenza viruses is required for the protec-
tion of the human host. The development of the vaccine should be dependent on several strategies 
such as epidemiological data of the previous pandemic influenza viruses, the presence of viruses 
in nature, and viruses responsible for infecting human population. The current influenza vaccines 
are live-attenuated influenza vaccines (LAIV), influenza-inactivated vaccine (IIV), recombinant 
subunit, DNA and vectored virus vaccine [37]. According to Centers for Disease Control and 
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Prevention (CDCs), the United States, available vaccines are of two types—trivalent and quadri-
valent flu vaccines. Trivalent influenza vaccine protects against influenza A(H1N1) and A(H3N2) 
as well as influenza B virus. The standard-dose trivalent flu shots are IIV 3, given to individuals 
between 18 and 64 years. The CDC has not recommended using LAIV as the vaccines for the year 
2017–2018 due to its low effectiveness found during 2013–2017. There are some limitations asso-
ciated with influenza virus vaccines suggesting that the circulating virus and the vaccine virus 
should be of same strains to give a high efficacy or else the vaccine might provide a false sense 
of security. The early influenza vaccination of individuals at a high risk might prevent influenza 
from becoming a pandemic. The Advisory Committee on Immunization Practices (ACIP) has 
recommended to primarily providing vaccination to children, pregnant women, individuals of 
age more than 65 years, and to people suffering from chronic ailments [38]. The other effective 
methods to control influenza are properly washing hands, use of masks, and covering mouth 
during coughing and sneezing, avoiding physical contacts with influenza-infected individuals, 
wearing gloves while working with infected poultry or swine, and the intake of effective antiviral 
medications.
9. Conclusions and future perspectives
Several factors play a pivotal role in preventing influenza virus infection such as increasing 
antigenic and genetic variants of influenza virus subtypes, the ability to cross the species bar-
rier, antiviral drug resistance, incapability in predicting the upcoming pandemic virus, the 
low probability of correctly matching the circulating and vaccine viruses, and the high cost 
of vaccination. Thus, a robust surveillance system that monitors the human influenza viruses 
will provide the candidate virus vaccine (CVV) as an adequate strategy required for prepar-
ing the pandemics. Apart from this, a comprehensive understanding at the molecular and 
genetic level of the avian and swine influenza virus will strengthen us in understanding their 
mechanism of re-assortment and transmission in humans. The veterinary vaccines designed 
for avian and swine population should be examined to evaluate their efficacy on the avian 
and swine influenza viruses. Furthermore, there is a crucial requirement of the universal vac-
cine that can target both seasonal and pandemic influenza viruses. Awareness regarding the 
prevention and control methods of influenza should be widely spread.
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